Verastem, Inc. (VSTM, Financial) has gained approval from the U.S. Food and Drug Administration for its Investigational New Drug application concerning VS-7375, an oral inhibitor targeting KRAS G12D mutations. This clearance enables Verastem to proceed with a Phase 1/2a clinical trial, anticipated to commence in mid-2025. The study aims to explore VS-7375’s efficacy in treating various advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers.
The upcoming trial will initially occur in the United States, with plans for possible global expansion. The research will focus on assessing both the safety and effectiveness of VS-7375, utilizing dosage information from preliminary findings by GenFleet Therapeutics. This approach is intended to expedite the trial's progress, particularly in identifying the optimal dosing levels for maximum therapeutic responses.
Additionally, an abstract detailing the preliminary dose escalation phase from the Phase 1/2 study of VS-7375, conducted by GenFleet, will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago from May 30 to June 3, 2025. This abstract remains confidential until May 22, 2025, when more detailed findings will be publicly disclosed.
Verastem plans to further explore the potential of VS-7375 in combination therapies during the Phase 2a trial, alongside monotherapy applications. The company's strategy involves multiple expansion cohorts to thoroughly evaluate the drug's impact on advanced solid tumors, aiming to enhance treatment options for those affected by these challenging cancers.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Verastem Inc (VSTM, Financial) is $13.00 with a high estimate of $20.00 and a low estimate of $8.00. The average target implies an upside of 82.71% from the current price of $7.12. More detailed estimate data can be found on the Verastem Inc (VSTM) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Verastem Inc's (VSTM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
